Pentasa (Mesalamine).
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and unpredictable group of illnesses affecting the gastrointestinal tracts of over 2 million Americans. Pentasa causes few side effects and is generally well tolerated.
Claussen
D W
DW
D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D019804:Mesalamine
D000636:Aminosalicylic Acids; D019804:Mesalamine